KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Fri Dec 12, 7:20PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase an aggregate of 101,200 shares of the Company's common stock. The exercise prices were $38.25 for the November 28 option grants, $38.31 for the December 4 option grants and $35.12 for the December 12 option grants, each of which was the closing trading price on the date of each grant. The stock options were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
KYTH: 34.11 (+0.79)
Strength Seen in Kythera (KYTH): Stock Moves 5.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:25AM CST
Kythera (KYTH) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
BIIB: 340.89 (+5.13), KYTH: 34.11 (+0.79), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)
KYTHERA Biopharmaceuticals to Present at the Goldman Sachs US Emerging / SMID Cap Growth Conference
GlobeNewswire - Fri Nov 14, 4:18PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York.
KYTH: 34.11 (+0.79)
Kythera net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:18AM CST
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals' (KYTH) CEO Keith Leonard on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:45PM CST
KYTH: 34.11 (+0.79)
Kythera misses 3Q profit forecasts
Automated Insights - Mon Nov 10, 6:24PM CST
CALABASAS, Calif. (AP) _ Kythera Biopharmaceuticals Inc. (KYTH) on Monday reported a loss of $22.5 million in its third quarter.
KYTH: 34.11 (+0.79)
KYTHERA misses by $0.11
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:22PM CST
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments.
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals to Release Third Quarter 2014 Operating Results
GlobeNewswire - Mon Nov 03, 5:30PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its third quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, November 10, 2014.
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
GlobeNewswire - Mon Aug 11, 3:13PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational drug, ATX-101 (deoxycholic acid), as an injectable treatment for the reduction of submental fat. The NDS is supported by results from two pivotal Phase III trials, REFINE-1 and REFINE-2, which were reported in late 2013. In these trials, the majority of ATX-101 patients had a visible reduction in fat under the chin and reported significant improvement in the visual and emotional impact of treatment.
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results
GlobeNewswire - Thu Aug 07, 3:45PM CDT
KYTHERA Biopharmaceuticals, Inc.(Nasdaq:KYTH) today reported financial results for its second quarter 2014 and provided an update on recent accomplishments.
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals to Release Second Quarter 2014 Operating Results
GlobeNewswire - Thu Jul 31, 3:43PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its second quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, August 7, 2014.
KYTH: 34.11 (+0.79)
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Application
GlobeNewswire - Thu Jul 10, 3:32PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review. The NDA will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. The PDUFA date is the goal date for the FDA to complete its review of the NDA.
KYTH: 34.11 (+0.79)
MarketMeSuite pilots Constant Contact's Small Business Innovation Program and announces new Constant Contact integration
Business Wire - Wed Feb 19, 8:00AM CST
MarketMeSuite (MarketMeSuite.com), the leading social media management and marketing platform for small businesses and professionals, has integrated with Constant Contact, launched on Constant Contact's MarketPlace, and has been named the first technology partner to join Constant Contact's Small Business Innovation program.
KYTH: 34.11 (+0.79), CTCT: 38.11 (+0.51)